Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.

Postgraduate medicine

Volumn 125, Issue 3, 2013, Pages 136-144

  Herrmann, Kathrin ^a   Frias, Juan P ^b   Edelman, Steven V ^b   Lutz, Karen ^b   Shan, Kevin ^b   Chen, Steven ^b   Maggs, David ^b   Kolterman, Orville G ^b  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN; PRAMLINTIDE;

ADULT; ARTICLE; BODY WEIGHT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN; ISLET AMYLOID POLYPEPTIDE; MALE;

EID: 84882238946     PISSN: None     EISSN: 19419260     Source Type: None    
DOI: 10.3810/pgm.2013.05.2635     Document Type: Article

References (0)